The Children's International Mucositis Evaluation Scale Is Valid and Reliable for the Assessment of Mucositis Among Brazilian Children With Cancer

Paiva, Bianca Sakamoto Ribeiro; Barroso, Eliane Marçon; Cadamuro, Sandra Andrade; Paula, Lia Alexandre Botelho de; Pirola, William Eduardo; Serrano, Claudia Valéria Maseti Pimenta; Paiva, Carlos Eduardo

doi:10.1016/j.jpainsymman.2018.07.015

Cited by 11 publications

(26 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It presents a total of seven items, related to mouth or throat pain, pain with swallowing, food related pains, pain related to fluid intake, use of pain medication, use of medication for pain in the mouth or throat and the presence of ulcerated lesions 25. The Brazilian version of self-applied and proxy ChIMES was considered culturally valid and reliable for paediatric patients and renamed CHIMES-BR 30…”

Section: Methodsmentioning

confidence: 99%

Symptom screening in paediatrics tool for screening multiple symptoms in Brazilian patients with cancer: a cross-sectional validation study

et al. 2019

Self Cite

View full text Add to dashboard Cite

ObjectiveThe objective of this study was to translate, culturally adapt and validate the Symptom Screening in Paediatrics Tool (SSPedi) into the Brazilian Portuguese language to be used by paediatric oncology patients in Brazil.DesignA descriptive, cross-sectional study that follows an established methodology for translation and cultural adaptation, developed in two phases: phase I, linguistic translation and cultural adaptation of the SSPedi scale and phase II, psychometric properties evaluation.SettingChildren’s Hospital for Cancer Treatment in Latin America.ParticipantsPaediatric patients between 7 and 18 years of age and proxies of patients between 2 and 6 years of age, diagnosed with cancer and undergoing chemotherapy treatment. Patients and proxies with significant neuropsychiatric disorders and/or visual impairment that prevented the ability to read were excluded.Primary outcome measuresConstruct validation of SSPedi using convergent validity and contrasted groups. Reliability was evaluated using Cronbach’s alpha test and assessing the retest using the intraclass correlation coefficient (ICC).ResultsThe psychometric properties of the symptom screening tool were evaluated using 157 participants, of which 116 were patients and 41 were proxies. Convergent validity and hypothesised correlations (Spearman’s r>0.4) were confirmed for both self- and proxy-reported versions of the assessment tool. No significant differences found between the two contrasting groups. Assessment of SSPedi resulted in an internal consistency of reliability of α=0.77 (95% CI 0.70 to 0.82) for the self and α=0.81 (95% CI 0.71 to 0.88) for the proxy and overall reproducibility ICC values of (95% CI), 0.54 (0.15 to 0.77) and 0.77 (0.64 to 0.86).ConclusionSSPedi was found to be culturally and linguistically adaptable and considered valid and reliable for use by paediatric oncology patients in Brazil. The new translated and adapted version was named SSPedi-BR.

show abstract

Section: Methodsmentioning

confidence: 99%

Symptom screening in paediatrics tool for screening multiple symptoms in Brazilian patients with cancer: a cross-sectional validation study

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…De modo ainda mais violento, ela pode aumentar a morbidade e a mortalidade (Hashemi et al, 2015), além de aumentar os níveis de estresse do paciente, principalmente o pediátrico. Por todas essas complicações, a detecção e principalmente a avaliação dessas complicações do tratamento do câncer pediátrico são essenciais (Paiva et al, 2018).…”

Section: Mucosite Oralunclassified

“…(Castro et al, 2013) Os efeitos colaterais da terapia antineoplásica devem ser tratados paralelamente à doença. (Paiva et al, 2018). São variados e, de modo geral, seu acometimento não se limita a um tipo, dependendo da terapia adotada no casoquimioterapia, radioterapia ou os doise das condições particulares do paciente.…”

Section: Introductionunclassified

“…Elas interferem na integridade e na função da cavidade oral e, em pacientes pediátricos, podem comprometer até as áreas da formação dentária e da formação óssea. (Paiva et al, 2018). A mucosite oral é um evento biológico causado por fatores do tratamento e fatores relacionados ao paciente (Otmani et al, 2011), entre eles: o tipo de câncer, o grau de supressão da medula óssea (Bulut;Tüfekci, 2016), a toxicidade do medicamento, a dosagem, o intervalo entre os ciclos de tratamento, a associação da radioterapia, a saúde geral do paciente, suscetibilidade aos agentes quimioterápicos, condição dentária e higiene oral do paciente (Castro et al, 2013 ).…”

Section: Introductionunclassified

“…(Mendonça et al, 2015) A mucosite também pode ser agravada por aspectos locais. (Paiva et al, 2018) Esses fatores estão entre os que determinam a suscetibilidade do paciente à mucosite oral, como demonstram 40% das terapias anticancegínenas de dose padrão e 50% das terapias de alta dose. Esse percentual aumenta em até 90% quando há quimioterapias combinadas para tratamento do câncer infantil.…”

Section: Introductionunclassified

See 2 more Smart Citations

Mucosite oral em crianças com câncer: dificuldades de avaliação e de terapia efetiva

Muniz

Holanda

Abreu

et al. 2021

RSD

View full text Add to dashboard Cite

O câncer é um problema de saúde pública no mundo e, em crianças, a incidência de aumento é de cerca de 1% ao ano. Apesar da eficácia, a terapia antineoplásica provoca efeitos de significativa toxicidade, muitas vezes causando a hospitalização do paciente, dificuldades de continuação da oncoterapia ou não readequação do tratamento para a não progressão da doença. A mucosite oral é um dos efeitos deletérios mais comuns; causa dor, afeta a fala e a nutrição e torna o paciente suscetível à septicemia. Em crianças, a frequência da mucosite oral situa-se em torno de 65%. Suas manifestações são avaliadas por meio de escalas diferentes e tratadas com protocolos distintos. O objetivo deste trabalho é verificar, em uma revisão sistemática da literatura, o estado da arte da avaliação da mucosite oral em crianças sob tratamento oncológico. Estudos mostraram que a avaliação é fundamental para estabelecer as estratégias de tratamento, que protocolos e escalas utilizadas são inconsistentes e que inexiste um sistema viável e válido para pontuar a mucosite infantil causada por câncer, impedindo uma intervenção terapêutica mais efetiva. Concluiu-se que a Children’s International Mucositis Evaluation Scale vem sendo a escala de maior aceitabilidade e validade por seu critérios.

show abstract

Oral mucositis assessment in pediatric and adolescent oncological patients: A systematic review

Soares,

de Farias Gabriel,

Kirschnick

et al. 2024

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Oral mucositis (OM) is a prevalent acute adverse effect of various cancer treatments. Accurate assessment of OM is vital for effective prevention and treatment strategies. However, a lack of validated pediatric instruments for evaluating OM can lead to unreliable data, and hinder interventional and epidemiological research. This study aims to evaluate the methods used for assessing OM in pediatric oncology patients. A systematic review of four databases and a manual search yielded 113 articles. Nine different scales were identified, with the World Health Organization (WHO) scale being the most commonly used (61.9%). The Children's International Mucositis Evaluation Scale (ChIMES) was used in 7.9% of the studies. Of the 8155 pediatric patients evaluated, 47.7% had both hematological malignancies and malignant solid tumors, while 46% had solely hematological malignancies. Despite the prevalence of the WHO scale, it lacks pediatric‐specific criteria. Future OM research should incorporate validated tools like ChIMES for improved pediatric assessment.

show abstract

The Children's International Mucositis Evaluation Scale Is Valid and Reliable for the Assessment of Mucositis Among Brazilian Children With Cancer

Abstract: The Portuguese self-reported and proxy versions of ChIMES were considered to be culturally adapted, valid, and reliable for Brazilian pediatric patients ranging from an age of one month to 18 years and were named ChIMES-BR.

Cited by 11 publications

References 19 publications

Symptom screening in paediatrics tool for screening multiple symptoms in Brazilian patients with cancer: a cross-sectional validation study

Symptom screening in paediatrics tool for screening multiple symptoms in Brazilian patients with cancer: a cross-sectional validation study

Mucosite oral em crianças com câncer: dificuldades de avaliação e de terapia efetiva

Oral mucositis assessment in pediatric and adolescent oncological patients: A systematic review

Contact Info

Product

Resources

About